Navigation Links
FDA Examines Ways to Improve Consumer Understanding of Prescription Drug Ads
Date:6/20/2011

SILVER SPRING, Md., June 20, 2011 /PRNewswire-USNewswire/ -- Findings from three studies conducted by the U.S. Food and Drug Administration confirm that the way information is conveyed and displayed in printed drug advertising affects consumer understanding of prescription medications.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

The studies, designed by experts in FDA's Division of Drug, Marketing, Advertising and Communications (DDMAC) in the Center for Drug Evaluation and Research, examined ways to improve understanding of how consumers use the "brief summary" section of printed prescription drug ads.

The online edition of the journal "Medical Decision Making" published findings from the third study today.

The Federal Food, Drug, and Cosmetic Act specifies that print advertisements for prescription drugs and biological products are required to provide a true statement of information "in brief summary" about the advertised product's "side effects, contraindications, and effectiveness."  

"Some of the current approaches to fulfilling the brief summary requirement, while adequate from a regulatory perspective, are not optimal in communicating this important information to consumers," said Thomas Abrams, director of DDMAC. "FDA's research and policy development seeks to improve the presentation of this information so it is easier for consumers to read and understand."

Print ads for prescription drugs are often two (or more) pages long. The first page of the prescription drug ad may feature a picture, information about what the product is intended to be used for, and important information about the product's risks. The second page summarizes all the product's risks and may be presented as densely-packed text information.

In the first study, a serious risk was added to the first and second page of the ad.  In the second study, additional information about side effects was included on the second page.  The third study tested four different brief summary formats:

Traditional (block text paragraphs), Question and Answer (with headings framed in the form of questions), Highlights (based on the highlights section of the physician labeling), and Prescription Drug Facts Box (resembling the current Over the Counter Drug Facts label).

Key findings of the studies include:

  • Adding a serious risk did not hinder people's understanding of the risk information.
  • Including additional information about how often side effects occur and how long they may last did not hinder people's understanding of the risk information.
  • Participants who viewed the Drug Facts format were better able to recall risks than those who saw the traditional format.

FDA researchers Kathryn Aikin, Ph.D., Amie O'Donoghue, Ph.D., and Helen Sullivan, Ph.D., M.P.H., and Jack Swasy, Ph.D., from American University designed and led the three experimental studies.

A copy of "Randomized Trial of Risk Information Formats for Brief Summary in Direct-to-Consumer (DTC) Print Advertisements for Prescription Drugs" will be available in the September/October 2011 issue of "Medical Decision Making."

For more information:

Randomized Trial of Risk Information Formats for Brief Summary in Direct-to-Consumer (DTC) Print Advertisements for Prescription Drugs

Background on Prescription Drug Advertising

Division of Drug Marketing, Advertising and Communication (DDMAC) Research  

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Shelly Burgess, 301-796-4651, shelly.burgess@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AAHC Examines Nations Clinical Trials Infrastructure
2. New Data Examines the Effect of Adding a Statin to Optimized Treatment for Patients with Advanced Heart Failure
3. New White Paper Examines Advanced Mycoplasma Tests - How Real-Time PCR Analysis Helps Save Time and Money for Biopharmaceutical Manufacturers
4. Turning the Page in HIV Prevention Research: An AIDS Vaccine is Possible — AVAC Examines The Way Forward
5. New Report by BioTrends Examines the Treatment of Renal Anemia in China
6. New Second Edition of Pharmaceutical Patent Law Examines Critical Intersection of Patent Law and Food and Drug Law
7. New Sub-Analysis of RE-LY Trial Examines Pradaxa in Patients with Atrial Fibrillation Undergoing Cardioversion
8. UL White Paper Examines Key Implications of Growing Home Healthcare Industry
9. FDLIs Food and Drug Policy Forum Examines European GMO Rules
10. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
11. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Story Highlights: ... the health care industry is causing providers to review ... Deloitte offers a suite of solutions for health care ... cost optimization: labor resource analysis, revenue cycle optimization and ... outcomes and better economics ...
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
Breaking Medicine News(10 mins):